For example, the SELECT trial reported that semaglutide reduced the risk of MACE by 20% (Hazard Ratio (HR) 0.80, 95% confidence interval (CI) 0.720.90) in people with obesity but without diabetes, although several secondary outcomes did not reach statistical significance under hierarchical testing procedures
Rpondez notre court quiz et obtenez une recommandation de produit personnalise en fonction de vos rponses
Fralick M, Schneeweiss S, Patorno E (2017) Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor
Buysschaert M, Tennstedt D, Preumont V
What is Exenatide extended release (Bydureon BCise)
Berberine may potentiate glucose-lowering effects of diabetes medications, increasing hypoglycemia risk when combined with insulin, sulfonylureas, or meglitinides